Drugs / PROGRAMMED CELL DEATH 1 LIGAND 1
PROGRAMMED CELL DEATH 1 LIGAND 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03939234 | Apr 2019 → Mar 2021 | B-cell chronic lymphocytic leukemia | Lars Møller Pedersen | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PROGRAMMED CELL DEATH 1 LIGAND 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298070 ↗ |
| Known as | B7 homolog 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298070 ↗ |
| Known as | B7-h1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298070 ↗ |
| Known as | Cd-274 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298070 ↗ |
| Known as | PD-L1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03939234 ↗ |
| Known as | Programmed death ligand 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298070 ↗ |
| Route | Subcutaneous | “Vaccinating subcutaneously with PD-L1 and PD-L2 peptides” NCT03939234 ↗ |